1. Fenofibrate: influence on circulating lipids and side-effects in medium and long-term clinical use;Blane,1986
2. Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV);Rouffy;Arzneim Forsch (Drug Res),1976
3. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients;Schneider;Atheriosclerosis,1985
4. Mechanism of action of fenofibrate: new data;Pascal,1987
5. Increase in lipoprotein lipase activity after procetofen treatment in primary hyperlipoproteinemia;Ruba;Clin Ter Cardiovasc,1982